APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatomycoses Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Dermatomycoses Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025193 pages

Choose your research edition.

Industry ResearchDermatomycoses Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatomycoses Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Dermatomycoses Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatomycoses Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatomycoses Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Dermatomycoses Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dermatomycoses Drug include Vyome Biosciences Pvt Ltd, Viamet Pharmaceuticals Inc, TGV-Laboratories, Sol-Gel Technologies Ltd, Novan Inc, Helix BioMedix Inc, Dermala Inc, Daewoong Pharmaceutical Co Ltd and Blueberry Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dermatomycoses Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatomycoses Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatomycoses Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dermatomycoses Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Dermatomycoses Drug Segment by Company

Vyome Biosciences Pvt Ltd

Viamet Pharmaceuticals Inc

TGV-Laboratories

Sol-Gel Technologies Ltd

Novan Inc

Helix BioMedix Inc

Dermala Inc

Daewoong Pharmaceutical Co Ltd

Blueberry Therapeutics Ltd

Biolab Farmaceutica Ltda

Anacor Pharmaceuticals Inc

Dermatomycoses Drug Segment by Type

BB-2603

Dapaconazole

Clotrimazole

Others

Dermatomycoses Drug Segment by Application

Hospital

Clinic

Others

Dermatomycoses Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomycoses Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatomycoses Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomycoses Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatomycoses Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dermatomycoses Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Dermatomycoses Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Dermatomycoses Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Dermatomycoses Drug Industry Trends Table 2. Dermatomycoses Drug Industry Drivers Table 3. Dermatomycoses Drug Industry Opportunities and Challenges Table 4. Dermatomycoses Drug Industry Restraints Table 5. Global Dermatomycoses Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Dermatomycoses Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Dermatomycoses Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Dermatomycoses Drug Sales Market Share by Manufacturers Table 9. Global Dermatomycoses Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Dermatomycoses Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Dermatomycoses Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Dermatomycoses Drug Manufacturers, Product Type & Application Table 13. Global Dermatomycoses Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Dermatomycoses Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of BB-2603 Table 17. Major Manufacturers of Dapaconazole Table 18. Major Manufacturers of Clotrimazole Table 19. Major Manufacturers of Others Table 20. Global Dermatomycoses Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 21. Global Dermatomycoses Drug Sales by Type (2021-2026) & (W Units) Table 22. Global Dermatomycoses Drug Sales by Type (2027-2032) & (W Units) Table 23. Global Dermatomycoses Drug Sales Market Share by Type (2021-2026) Table 24. Global Dermatomycoses Drug Sales Market Share by Type (2027-2032) Table 25. Global Dermatomycoses Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Dermatomycoses Drug Revenue by Type (2021-2026) & (W Units) Table 27. Global Dermatomycoses Drug Revenue by Type (2027-2032) & (W Units) Table 28. Global Dermatomycoses Drug Revenue Market Share by Type (2021-2026) Table 29. Global Dermatomycoses Drug Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Others Table 33. Global Dermatomycoses Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Dermatomycoses Drug Sales by Application (2021-2026) & (W Units) Table 35. Global Dermatomycoses Drug Sales by Application (2027-2032) & (W Units) Table 36. Global Dermatomycoses Drug Sales Market Share by Application (2021-2026) Table 37. Global Dermatomycoses Drug Sales Market Share by Application (2027-2032) Table 38. Global Dermatomycoses Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Dermatomycoses Drug Revenue by Application (2021-2026) & (W Units) Table 40. Global Dermatomycoses Drug Revenue by Application (2027-2032) & (W Units) Table 41. Global Dermatomycoses Drug Revenue Market Share by Application (2021-2026) Table 42. Global Dermatomycoses Drug Revenue Market Share by Application (2027-2032) Table 43. Global Dermatomycoses Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Dermatomycoses Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Dermatomycoses Drug Sales Market Share by Region (2021-2026) Table 46. Global Dermatomycoses Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 47. Global Dermatomycoses Drug Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. North America Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 50. North America Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 51. Europe Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Europe Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 53. Europe Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 54. Asia Pacific Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Asia Pacific Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 56. Asia Pacific Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 57. South America, Middle East and Africa Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. South America, Middle East and Africa Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 59. South America, Middle East and Africa Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 60. Global Dermatomycoses Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Dermatomycoses Drug Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Dermatomycoses Drug Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Dermatomycoses Drug Revenue Market Share by Region (2021-2026) Table 64. Global Dermatomycoses Drug Revenue Market Share by Region (2027-2032) Table 65. Vyome Biosciences Pvt Ltd Company Information Table 66. Vyome Biosciences Pvt Ltd Business Overview Table 67. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio Table 69. Vyome Biosciences Pvt Ltd Recent Development Table 70. Viamet Pharmaceuticals Inc Company Information Table 71. Viamet Pharmaceuticals Inc Business Overview Table 72. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 74. Viamet Pharmaceuticals Inc Recent Development Table 75. TGV-Laboratories Company Information Table 76. TGV-Laboratories Business Overview Table 77. TGV-Laboratories Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. TGV-Laboratories Dermatomycoses Drug Product Portfolio Table 79. TGV-Laboratories Recent Development Table 80. Sol-Gel Technologies Ltd Company Information Table 81. Sol-Gel Technologies Ltd Business Overview Table 82. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio Table 84. Sol-Gel Technologies Ltd Recent Development Table 85. Novan Inc Company Information Table 86. Novan Inc Business Overview Table 87. Novan Inc Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novan Inc Dermatomycoses Drug Product Portfolio Table 89. Novan Inc Recent Development Table 90. Helix BioMedix Inc Company Information Table 91. Helix BioMedix Inc Business Overview Table 92. Helix BioMedix Inc Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Helix BioMedix Inc Dermatomycoses Drug Product Portfolio Table 94. Helix BioMedix Inc Recent Development Table 95. Dermala Inc Company Information Table 96. Dermala Inc Business Overview Table 97. Dermala Inc Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Dermala Inc Dermatomycoses Drug Product Portfolio Table 99. Dermala Inc Recent Development Table 100. Daewoong Pharmaceutical Co Ltd Company Information Table 101. Daewoong Pharmaceutical Co Ltd Business Overview Table 102. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio Table 104. Daewoong Pharmaceutical Co Ltd Recent Development Table 105. Blueberry Therapeutics Ltd Company Information Table 106. Blueberry Therapeutics Ltd Business Overview Table 107. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio Table 109. Blueberry Therapeutics Ltd Recent Development Table 110. Biolab Farmaceutica Ltda Company Information Table 111. Biolab Farmaceutica Ltda Business Overview Table 112. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio Table 114. Biolab Farmaceutica Ltda Recent Development Table 115. Anacor Pharmaceuticals Inc Company Information Table 116. Anacor Pharmaceuticals Inc Business Overview Table 117. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 119. Anacor Pharmaceuticals Inc Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Dermatomycoses Drug Distributors List Table 123. Dermatomycoses Drug Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Dermatomycoses Drug Product Image Figure 2. Global Dermatomycoses Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatomycoses Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Dermatomycoses Drug Sales (2021-2032) & (W Units) Figure 5. Global Dermatomycoses Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Dermatomycoses Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. BB-2603 Image Figure 9. Dapaconazole Image Figure 10. Clotrimazole Image Figure 11. Others Image Figure 12. Global Dermatomycoses Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 13. Global Dermatomycoses Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Dermatomycoses Drug Sales Market Share by Type (2021-2032) Figure 15. Global Dermatomycoses Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 16. Global Dermatomycoses Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Dermatomycoses Drug Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Others Image Figure 21. Global Dermatomycoses Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Dermatomycoses Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Dermatomycoses Drug Sales Market Share by Application (2021-2032) Figure 24. Global Dermatomycoses Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Dermatomycoses Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Dermatomycoses Drug Revenue Market Share by Application (2021-2032) Figure 27. North America Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 28. North America Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 29. U.S. Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Canada Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Mexico Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 34. Germany Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. France Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. U.K. Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Italy Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Netherlands Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 41. China Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Japan Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. South Korea Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Southeast Asia Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. India Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Australia Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Dermatomycoses Drug Sales Market Share by Country (2021-2032) Figure 49. Brazil Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South Africa Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Saudi Arabia Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Turkey Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Argentina Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. UAE Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Egypt Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Chile Dermatomycoses Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Global Dermatomycoses Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Dermatomycoses Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Dermatomycoses Drug Revenue (2021-2032) & (US$ Million) Figure 60. North America Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Dermatomycoses Drug Revenue (2021-2032) & (US$ Million) Figure 62. Europe Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Dermatomycoses Drug Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Dermatomycoses Drug Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Dermatomycoses Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Dermatomycoses Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • BB-2603
  • Dapaconazole
  • Clotrimazole
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Vyome Biosciences Pvt Ltd
  • Viamet Pharmaceuticals Inc
  • TGV-Laboratories
  • Sol-Gel Technologies Ltd
  • Novan Inc
  • Helix BioMedix Inc
  • Dermala Inc
  • Daewoong Pharmaceutical Co Ltd
  • Blueberry Therapeutics Ltd
  • Biolab Farmaceutica Ltda
  • Anacor Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dermatomycoses Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dermatomycoses Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Dermatomycoses Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Dermatomycoses Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Dermatomycoses Drug Market Dynamics
  1. 2.1 Dermatomycoses Drug Industry Trends
  2. 2.2 Dermatomycoses Drug Industry Drivers
  3. 2.3 Dermatomycoses Drug Industry Opportunities and Challenges
  4. 2.4 Dermatomycoses Drug Industry Restraints
3 Dermatomycoses Drug Market by Manufacturers
  1. 3.1 Global Dermatomycoses Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Dermatomycoses Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Dermatomycoses Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Dermatomycoses Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dermatomycoses Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Dermatomycoses Drug Manufacturers, Product Type & Application
  7. 3.7 Global Dermatomycoses Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dermatomycoses Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dermatomycoses Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dermatomycoses Drug Tier 1, Tier 2, and Tier 3
4 Dermatomycoses Drug Market by Type
  1. 4.1 Dermatomycoses Drug Type Introduction
  2. 4.1.1 BB-2603
  3. 4.1.2 Dapaconazole
  4. 4.1.3 Clotrimazole
  5. 4.1.4 Others
  6. 4.2 Global Dermatomycoses Drug Sales by Type
  7. 4.2.1 Global Dermatomycoses Drug Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Dermatomycoses Drug Sales by Type (2021-2032)
  9. 4.2.3 Global Dermatomycoses Drug Sales Market Share by Type (2021-2032)
  10. 4.3 Global Dermatomycoses Drug Revenue by Type
  11. 4.3.1 Global Dermatomycoses Drug Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Dermatomycoses Drug Revenue by Type (2021-2032)
  13. 4.3.3 Global Dermatomycoses Drug Revenue Market Share by Type (2021-2032)
5 Dermatomycoses Drug Market by Application
  1. 5.1 Dermatomycoses Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatomycoses Drug Sales by Application
  6. 5.2.1 Global Dermatomycoses Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dermatomycoses Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Dermatomycoses Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Dermatomycoses Drug Revenue by Application
  10. 5.3.1 Global Dermatomycoses Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dermatomycoses Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Dermatomycoses Drug Revenue Market Share by Application (2021-2032)
6 Global Dermatomycoses Drug Sales by Region
  1. 6.1 Global Dermatomycoses Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatomycoses Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Dermatomycoses Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Dermatomycoses Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Dermatomycoses Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Dermatomycoses Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Dermatomycoses Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Dermatomycoses Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Dermatomycoses Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Dermatomycoses Drug Revenue by Region
  1. 7.1 Global Dermatomycoses Drug Revenue by Region
  2. 7.1.1 Global Dermatomycoses Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Dermatomycoses Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Dermatomycoses Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Dermatomycoses Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Dermatomycoses Drug Revenue (2021-2032)
  8. 7.2.2 North America Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Dermatomycoses Drug Revenue (2021-2032)
  11. 7.3.2 Europe Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Dermatomycoses Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Dermatomycoses Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Dermatomycoses Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Vyome Biosciences Pvt Ltd
  2. 8.1.1 Vyome Biosciences Pvt Ltd Company Information
  3. 8.1.2 Vyome Biosciences Pvt Ltd Business Overview
  4. 8.1.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio
  6. 8.1.5 Vyome Biosciences Pvt Ltd Recent Developments
  7. 8.2 Viamet Pharmaceuticals Inc
  8. 8.2.1 Viamet Pharmaceuticals Inc Company Information
  9. 8.2.2 Viamet Pharmaceuticals Inc Business Overview
  10. 8.2.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  12. 8.2.5 Viamet Pharmaceuticals Inc Recent Developments
  13. 8.3 TGV-Laboratories
  14. 8.3.1 TGV-Laboratories Company Information
  15. 8.3.2 TGV-Laboratories Business Overview
  16. 8.3.3 TGV-Laboratories Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 TGV-Laboratories Dermatomycoses Drug Product Portfolio
  18. 8.3.5 TGV-Laboratories Recent Developments
  19. 8.4 Sol-Gel Technologies Ltd
  20. 8.4.1 Sol-Gel Technologies Ltd Company Information
  21. 8.4.2 Sol-Gel Technologies Ltd Business Overview
  22. 8.4.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio
  24. 8.4.5 Sol-Gel Technologies Ltd Recent Developments
  25. 8.5 Novan Inc
  26. 8.5.1 Novan Inc Company Information
  27. 8.5.2 Novan Inc Business Overview
  28. 8.5.3 Novan Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novan Inc Dermatomycoses Drug Product Portfolio
  30. 8.5.5 Novan Inc Recent Developments
  31. 8.6 Helix BioMedix Inc
  32. 8.6.1 Helix BioMedix Inc Company Information
  33. 8.6.2 Helix BioMedix Inc Business Overview
  34. 8.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Portfolio
  36. 8.6.5 Helix BioMedix Inc Recent Developments
  37. 8.7 Dermala Inc
  38. 8.7.1 Dermala Inc Company Information
  39. 8.7.2 Dermala Inc Business Overview
  40. 8.7.3 Dermala Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Dermala Inc Dermatomycoses Drug Product Portfolio
  42. 8.7.5 Dermala Inc Recent Developments
  43. 8.8 Daewoong Pharmaceutical Co Ltd
  44. 8.8.1 Daewoong Pharmaceutical Co Ltd Company Information
  45. 8.8.2 Daewoong Pharmaceutical Co Ltd Business Overview
  46. 8.8.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio
  48. 8.8.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  49. 8.9 Blueberry Therapeutics Ltd
  50. 8.9.1 Blueberry Therapeutics Ltd Company Information
  51. 8.9.2 Blueberry Therapeutics Ltd Business Overview
  52. 8.9.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio
  54. 8.9.5 Blueberry Therapeutics Ltd Recent Developments
  55. 8.10 Biolab Farmaceutica Ltda
  56. 8.10.1 Biolab Farmaceutica Ltda Company Information
  57. 8.10.2 Biolab Farmaceutica Ltda Business Overview
  58. 8.10.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio
  60. 8.10.5 Biolab Farmaceutica Ltda Recent Developments
  61. 8.11 Anacor Pharmaceuticals Inc
  62. 8.11.1 Anacor Pharmaceuticals Inc Company Information
  63. 8.11.2 Anacor Pharmaceuticals Inc Business Overview
  64. 8.11.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  66. 8.11.5 Anacor Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dermatomycoses Drug Value Chain Analysis
  2. 9.1.1 Dermatomycoses Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dermatomycoses Drug Production Mode & Process
  6. 9.2 Dermatomycoses Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dermatomycoses Drug Distributors
  9. 9.2.3 Dermatomycoses Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst